Hormonal
FOXO3a variants are associated with increased human life span, with the minor allele conferring a higher odds of longevity (OR 2.75) in centenarians of Japanese descent, and this association has been replicated in diverse populations including German, Italian, Chinese, and Danish cohorts.
FOXO3a is a gene linked to longevity, particularly in the insulin/IGF-1 signaling pathway. While you cannot change your genes, understanding this pathway highlights the importance of metabolic health. Interventions that modulate insulin sensitivity and cellular stress response (like exercise and balanced nutrition) may leverage this genetic potential.
FOXO3a was first noted to be associated with longevity in a candidate gene study conducted in male centenarians of Japanese descent (65) and subsequently replicated in diverse samples of centenarians and long-lived individuals (66–69)... SNPs in two genes in this pathway (AKT1 and FOXO3a) were significantly associated with human life span.
Why this rating
Replicated across multiple independent candidate gene studies in diverse ethnicities, though missed by initial large-scale GWAS.
Source
The Search for Longevity and Healthy Aging Genes: Insights From Epidemiological Studies and Samples of Long-Lived Individuals
Joanne M. Murabito et al. · The Journals of Gerontology Series A · 2012
DOI 10.1093/gerona/gls089
More from this paper
- The ApoE E4 isoform is deleterious to longevity, while the E2 isoform is protective, with the E4 allele conferring up to an 8-15 fold increased risk for Alzheimer's disease and premature death from age-related conditions.Good
- Lower levels of IGF-1 are associated with longer life span in mice, and this region overlaps with human longevity quantitative trait loci, suggesting a conserved mechanism where IGF-1 regulation influences longevity.Moderate
- Resveratrol improves insulin sensitivity in older adults with impaired glucose tolerance, supporting its potential as an intervention to delay aging based on its effects on the insulin/IGF-1 pathway.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →